Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Inhaled QBW276 in Patients With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs QBW 276 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Jun 2019 Status changed from recruiting to completed.
- 26 Oct 2018 This trial has been Discontinued in Germany (end date: 2018-10-04)
- 25 Feb 2018 Planned End Date changed from 11 Sep 2019 to 1 Jan 2019.